Results 1 to 10 of about 5,477 (176)
STADE-HF (sST2 as a Help for Management of HF): A Pilot Study [PDF]
ESC Heart Failure, 2020 Aims Biomarkers are not recommended until now to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. The current study considered pre‐discharged sST2 values as a guide
Huet Fabien +2 more
exaly +4 more sources
sST2 as a value-added biomarker in heart failure [PDF]
Clinica Chimica Acta, 2020 Soluble suppression of tumorigenicity-2 (sST2) is a biomarker widely investigated during the last few years. Its role has become clear in pathological conditions such as fibrosis and inflammation. From translational research to laboratory medicine, considerable efforts have been made to elucidate the features of sST2 biomarker and to consider its ...
Eran Kalmanovich +2 more
exaly +3 more sources
Sex and age differences in sST2 in cardiovascular disease
Frontiers in Cardiovascular Medicine, 2023 AimsThe goal of this study was to determine whether sex and age differences exist for soluble ST2 (sST2) for several cardiovascular diseases (CVDs).MethodsWe examined sST2 levels using an ELISA kit for myocarditis (n = 303), cardiomyopathy (n = 293 ...
Danielle J. Beetler +30 more
doaj +3 more sources
sST2 and Heart Failure—Clinical Utility and Prognosis
Journal of Clinical Medicine, 2023 New parameters and markers are constantly being sought to help better assess patients with heart failure (HF). ST2 protein has gained interest as a potential biomarker in cardiovascular disease. It is known that the IL-33/ST2L system belongs to the cardioprotective pathway, which prevents the fibrosis, hypertrophy, and apoptosis of cardiomyocytes and ...
Magdalena Dudek +2 more
exaly +3 more sources
IJC Heart and Vasculature, 2021 Objectives: Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family. It is raised in various cardiovascular diseases, but its value in predicting disease severity or mortality outcomes has been controversial ...
, Ka Hou Li, Keith Sai Kit Leung
exaly +3 more sources
Serum sST2 levels predict severe exacerbation of asthma [PDF]
Respiratory Research, 2018 Background Neutrophilic inflammation is associated with poorly controlled asthma. Serum levels of sST2, a soluble IL-33 receptor, increase in neutrophilic lung diseases. We hypothesized that high serum sST2 levels in stable asthmatics are a predictor for
Masato Watanabe +11 more
doaj +3 more sources
Clinical and Prognostic Significance of sST2 in Heart Failure
Journal of the American College of Cardiology, 2019 Alberto Aimo +2 more
exaly +2 more sources
Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumors
Frontiers in Endocrinology, 2023 BackgroundSomatostatin receptor type 2 (SST2) expression is critical for the diagnosis and treatment of neuroendocrine tumors and is associated with improved patient survival.
Maria J. Klomp +13 more
doaj +1 more source
Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients
Diagnostics, 2023 Soluble suppression of tumorigenesis-2 (sST2) is an emerging biomarker for sepsis as well as for heart failure. We investigated the prognostic utility of sST2 for predicting clinical outcomes in hospitalized coronavirus disease 2019 (COVID-19) patients ...
Mikyoung Park +7 more
doaj +1 more source
Prognostic Value of sST2 in Heart Failure
Journal of Clinical Medicine, 2023 In recent years, there has been growing interest in the risk stratification for heart failure, and the use of multiple biomarkers to identify different pathophysiological processes associated with this condition. One such biomarker is soluble suppression of tumorigenicity-2 (sST2), which has shown some potential for integration into clinical practice ...
Sciatti E. +9 more
openaire +3 more sources